Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

PFIZER INC
Mes dernières consult.
Most popular
  Report  
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Pfizer Inc. : Pfizer Names Olivier Brandicourt as President and General Manager, Emerging Markets and Established Products Business Units

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/23/2012 | 01:35pm CEST

John Young Named President and General Manager, Primary Care Business Unit

Pfizer Inc. (NYSE: PFE) named Olivier Brandicourt as President and General Manager of the Emerging Markets and Established Products Business Units, effective June 1, 2012. He will succeed David Simmons, who is leaving Pfizer to become the Chairman and CEO of Pharmaceutical Product Development Inc. (PPD), a privately held global contract research organization.

"Olivier is ideally suited to take on this new role," said Ian Read, Pfizer Chairman and CEO. "He has more than 20 years of global experience in the pharmaceutical industry. Olivier is both a physician and proven business leader who understands the many challenges of today's changing industry and healthcare landscape."

Dr. Brandicourt has held senior positions at Pfizer across a range of disciplines, including medical and marketing, as well as country and regional management roles in Latin America, Europe, Canada, the United Kingdom and the United States. Most recently, he served as President and General Manager of the Primary Care Business Unit and is a member of the Pfizer Executive Leadership Team. He is an Honorary Fellow of the Royal College of Physicians in London and a trustee of the Children's Aid Society of New York.

John Young, currently Regional President of Europe and Canada for the Primary Care business, is appointed President and General Manager of the Primary Care Business Unit and will join the Company's Executive Leadership Team, effective June 1, 2012. Over his 25-year career with Pfizer, Mr. Young has held a number of commercial positions with the company, including country and regional management roles in Australia/New Zealand and the United Kingdom.

"John has a deep understanding of the primary care landscape and will be a strong leader for this significant part of our business. We are indeed fortunate to have such a deep bench of talented leaders who can quickly assume new roles and maintain our momentum," Read added.

"We thank David for his contributions throughout his 15-year career at Pfizer. Under his leadership, the Established Products Business Unit was created, expanding Pfizer's market reach while also helping to ensure patients have the access to high-quality, affordable medicines they need."

Pfizer Inc: Working Together for a Healthier World™

At Pfizer (NYSE: PFE), we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.

Pfizer Inc.
Media Contact:
Joan Campion, 212-733-2798
or
Investors Contact:
Chuck Triano, 212-733-3901


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER INC
05/26WATCH : First Viagra ad aired on UK TV
AQ
05/26PFIZER : will have to cut price of AML drug Mylotarg after NICE ruling
AQ
05/26GLOBAL ACTIVE PHARMACEUTICAL INGREDI : Pfizer, Inc., Novartis International AG, ..
AQ
05/25PFIZER : Biosimilar RETACRIT® epoetin alfa-epbx Approved by U.S. FDA
AQ
05/25PFIZER : Roivant Expands Senior Leadership with Key Hires
AQ
05/25PFIZER : Investigators at Pfizer Report Findings in Breast Cancer (Real-world ev..
AQ
05/25STUDY FINDINGS FROM PFIZER PROVIDE N : Adapting and Evaluating...
AQ
05/25PFIZER : Data from Pfizer Provide New Insights into Asthma (Proteomic analysis o..
AQ
05/25PFIZER : Oncology to Showcase Clinical Advances from its Growing Portfolio and R..
AQ
05/25INVACARE CORPORATION : Appoints Petra Danielsohn-Weil, PhD, to Board of Director..
AQ
More news
News from SeekingAlpha
2015Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2015 Update 
2015Antibiotics Stocks To Benefit From 21st Century Cures Act 
2015ISIS PHARMA STOCK DROPS ON GOOD NEWS : Re-Evaluating The Bull Case 
2015DOW DOGS : 14.63% More Returns From 5 Lowest Priced As Of August 6 Per indexArb 
2015Pfizer's GL-2045 an Orphan Drug for CIDP 
Financials ($)
Sales 2018 54 391 M
EBIT 2018 20 753 M
Net income 2018 12 828 M
Debt 2018 21 840 M
Yield 2018 3,83%
P/E ratio 2018 15,89
P/E ratio 2019 15,13
EV / Sales 2018 4,24x
EV / Sales 2019 4,05x
Capitalization 209 B
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 39,6 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer & Director
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC208 713
JOHNSON & JOHNSON-11.45%325 801
PFIZER-0.91%208 713
NOVARTIS-8.30%194 397
ROCHE HOLDING LTD.-9.17%189 708
MERCK AND COMPANY5.01%158 970